MedCity News September 4, 2024
Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players.
Sales of Eli Lilly’s chronic weight management drug Zepbound are growing by leaps and bounds, but the product is expensive to manufacture and the pharmaceutical giant remains pressed to make enough to meet demand. Meanwhile, other companies are taking market share with compounded versions.
Lilly has found a way to reach more patients with its fast-growing product while also taking a competitive stand against Zepbound knockoffs: It’s offering the drug directly to patients at a steep discount. Supplying...
Today's Sponsors
Today's Sponsor